Intensive Care Medicine

, Volume 35, Issue 4, pp 582–584

On track to limit antifungal overuse!

  • Philippe Eggimann
  • Frédéric Lamoth
  • Oscar Marchetti
Editorial

Invasive candidiasis (IC) has emerged as a main cause of morbidity and mortality among critically ill patients. Candida colonization at multiple sites promoted by prolonged exposure to antibiotics, intravascular devices for parenteral nutrition or renal replacement therapy, and complicated abdominal surgery are associated with the development of IC [1]. The gastrointestinal tract and endovascular catheters are thus the most common sources of IC [2].

Early recognition and appropriate management of IC are crucial for outcome [3, 4]. However, the sensitivity of conventional blood cultures remains limited. The utility of fungal blood markers such as beta-(1,3)-d-glucan or mannan/antimannan and PCR testing for the early diagnosis of IC needs to be confirmed in the ICU setting [5, 6]. Pending the conclusion on ongoing investigations and on the role of composite clinical scores which may improve the prediction of IC, therapeutic decisions remain essentially based on the clinical risk profile [7]. This approach results in a low threshold for starting antifungals (prophylactic, pre-emptive or empirical treatment) and in a high number needed to treat to target a single IC episode [8, 9].

It has been suggested that the epidemiological shift from Candida albicans to species intrinsically resistant (Candida krusei) or with decreased susceptibility to azoles (Candida glabrata) observed in some institutions is a consequence of an overuse of antifungals [10, 11]. While the efficacy of fluconazole as first-line therapy of IC is being challenged, well tolerated but expensive alternative broad-spectrum antifungal agents are now available and will be recommended in the updated IDSA guidelines for the management of IC [11, 12, 13, 14]. These new drugs are expected to impact positively on the outcome of IC; however, the economical and ecological consequences of their increasing use are difficult to predict [15, 16]. Despite an improved therapeutic armamentarium, there is thus an urgent need for new management strategies for better targeting the use of antifungal agents.

This is the aim of the paper published by Pérez-Para et al. [17] in the current issue of the Journal, in which a frequent not evidence-based trigger for starting antifungal therapy is challenged. In a retrospective analysis the authors suggest, in contrast to the common opinion, that a central venous catheters (CVC) tip culture positive for Candida spp. is not synonymous of IC or of increased risk for developing IC. Among 215 non-neutropenic critically ill patients with a positive CVC culture at a single academic institution, a subgroup of 58 patients (27%) with negative blood cultures drawn within 7 days before and 7 days after catheter removal was analyzed. Twenty patients received antifungals and only one developed IC (i.e., 2% of cases), suggesting that the number needed to treat a single IC episode would be substantial. Independent predictors of poor outcome were a McCabe score corresponding to ultimately fatal underlying disease and the presence of severe sepsis, septic shock or multiorgan failure. The authors concluded that antifungal treatment did not impact on the clinical outcome in these patients [17].

In patients with bloodstream infection removal of the CVC has been suggested in previous investigations to accelerate the clearance of bacteremia or fungemia. In critically ill patients with sepsis and no documented infectious focus it is common practice to promptly remove and/or exchange the indwelling intravascular devices. In the absence of concomitant positive blood cultures, the clinical signification of a catheter tip culture positive for Candida spp. remains to be determined [18]. Nevertheless, in order to avoid acute and late complications of IC, many clinicians start antifungal therapy in this setting. The study by Pérez-Para et al. suggests that this subgroup of patients should not receive antifungal therapy.

However, many questions remain unanswered. The reason for CVC removal and culture are not specified. Did these patients present a sepsis of unknown origin or was the device removed for end of use and routinely sent for culture despite absence of any symptoms and signs of infection? [18]. The cut-off value of one colony forming unit used for defining catheter colonization may have selected a subgroup of patients with an extremely low level of CVC colonization: whether a higher colony count is associated with an increased risk of IC remains unknown. The significance of a positive catheter culture for Candida spp. in the absence of candidemia and of clinical signs of infection may differ according to the presence or absence of a colonization at other sites. Although the dynamics of colonization assessed semi-quantitatively by the colonization index has been shown to predict the risk of IC, this information is lacking in the present study [8, 9, 12]. Simultaneous sampling of blood cultures from a catheter line and by peripheral venipuncture is recommended. Results of blood cultures obtained through the colonized device have, however, not been reported. Whether a positive result or other clinical characteristics did influence the decision to start an antifungal therapy remains unknown. Further, blood cultures were drawn within 7 days before or after CVC removal: is such a large time window reasonable to exclude candidemia in a patient with a positive CVC culture? Finally, one may challenge the decision to a priori exclude from the analysis the 64 patients with a concomitant candidemia, the 44 patients in whom no blood cultures have been drawn and the 26 children. These selection criteria might have biased the retrospective assessment of the target population [17].

Beyond these major limitations, these data suggest that a catheter tip culture positive for Candida spp. in the absence of candidemia should not be automatically considered as an IC or a condition at high risk for developing IC. This observation suggests a reduction of the undiscriminated use of antifungal agents in this setting. However, this conclusion needs to be confirmed in prospective investigations assessing in which subset of patients with a positive CVC tip culture withholding or de-escalating antifungals is safe. These should be designed by defining the underlying conditions (risk factors, colonization, clinical signs of infection), by standardizing the diagnostic procedures (CVC cultures, blood cultures) and by distinguishing the type of intervention (i.e., prophylactic or pre-emptive/empirical antifungal therapy).

References

  1. 1.
    Eggimann P, Garbino J, Pittet D (2003) Epidemiology of Candida species infections in critically ill non-immunosuppressed patient. Lancet Infect Dis 3:685–702PubMedCrossRefGoogle Scholar
  2. 2.
    Nucci M, Anaissie E (2001) Revisiting the source of candidemia: skin or gut? Clin Infect Dis 33:1959–1967PubMedCrossRefGoogle Scholar
  3. 3.
    Raad I, Hanna H, Boktour M, Girgawy E, Danawi H, Mardani M, Kontoyiannis D, Darouiche R, Hachem R, Bodey GP (2004) Management of central venous catheters in patients with cancer and candidemia. Clin Infect Dis 38:1119–1127PubMedCrossRefGoogle Scholar
  4. 4.
    Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden DT (2006) Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43:25–31PubMedCrossRefGoogle Scholar
  5. 5.
    Prella M, Bille J, Pugnale M, Duvoisin B, Cavassini M, Calandra T, Marchetti O (2005) Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies. Diagn Microbiol Infect Dis 51:95–101PubMedCrossRefGoogle Scholar
  6. 6.
    Senn L, Robinson JO, Schmidt S, Knaup M, Asahi N, Satomura S, Matsuura S, Duvoisin B, Bille J, Calandra T, Marchetti O (2008) 1, 3-Beta-d-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 46:878–885PubMedCrossRefGoogle Scholar
  7. 7.
    Leon C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Alvarez-Lerma F, Garnacho-Montero J, León MA, EPCAN Study Group (2006) A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 34:730–737PubMedCrossRefGoogle Scholar
  8. 8.
    Eggimann P, Garbino J, Pittet D (2003) Management of Candida species infections in critically ill patient. Lancet Infect Dis 3:772–785PubMedCrossRefGoogle Scholar
  9. 9.
    Mean M, Marchetti O, Calandra T (2008) Bench-to-bedside review: Candida infections in the intensive care unit. Crit Care 12:204PubMedCrossRefGoogle Scholar
  10. 10.
    Pfaller MA, Diekema DJ, Gibbs DL (2007) Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 45:1735–1745PubMedCrossRefGoogle Scholar
  11. 11.
    Brion LP, Uko SE, Goldman DL (2007) Risk of resistance associated with fluconazole prophylaxis: systematic review. J Infect 54:521–529PubMedCrossRefGoogle Scholar
  12. 12.
    Guery BP, Arendrup MC, Auzinger G, Azoulay E, Borges Sá M, Johnson EM, Müller E, Putensen C, Rotstein C, Sganga G, Venditti M, Zaragoza Crespo R, Kullberg BJ (2009) Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part II. Treatment. Intensive Care Med. doi:10.1007/s00134-008-1339-6
  13. 13.
    Playford EG, Eggimann P, Calandra T (2008) Antifungals in the ICU. Curr Opin Infect Dis 21:610–619PubMedCrossRefGoogle Scholar
  14. 14.
  15. 15.
    Forrest GN, Weekes E, Johnson JK (2008) Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect 56:126–129PubMedCrossRefGoogle Scholar
  16. 16.
    Johnson E, Espinel-Ingroff A, Szekely A, Hockey H, Troke P (2008) Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies. Int J Antimicrob Agents 32:511–514PubMedCrossRefGoogle Scholar
  17. 17.
    Pérez-Parraz A, Munoz P, Guinea J, Martin-Rabadan P, Guembe M, Bouza E (2009) Is Candida colonization of central vascular catheter in non-candidemic, non-neutropenic patients an indicator for antifungals? Intensive Care Med. doi:10.1007/s00134-009-1431-6
  18. 18.
    Eggimann P (2007) Diagnosis of intravascular catheter infection. Curr Opin Infect Dis 20:353–359PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Philippe Eggimann
    • 1
  • Frédéric Lamoth
    • 2
  • Oscar Marchetti
    • 2
  1. 1.Department of Adult Intensive Care and Burn CenterCentre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL)LausanneSwitzerland
  2. 2.Infectious Diseases Service, Department of MedicineCentre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL)LausanneSwitzerland

Personalised recommendations